Beta-2 adrenergic receptor

Assets acting on this target.

Class
Beta-2 adrenergic receptor agonist
Pathway
airway smooth-muscle relaxation / bronchodilation
Notes
original target text: β2-adrenergic receptor

The beta-2 adrenergic receptor is a cell-surface receptor found abundantly on the smooth muscle that surrounds airways in the lungs. It belongs to the G protein-coupled receptor family, and its natural ligands are adrenaline and, to a lesser extent, noradrenaline. When activated, this receptor triggers relaxation of airway smooth muscle, which widens the airway lumen and eases airflow. This effect is exploited pharmacologically through beta-2 agonists, small molecules that mimic the natural ligand at this receptor. Short-acting agonists produce rapid but relatively brief bronchodilation, useful for quickly relieving acute breathlessness, while long-acting agonists provide more sustained relaxation for ongoing symptom control. Because the receptor also exists in other tissues, agonism is not perfectly confined to the lungs, which underlies some of the class's known side effects. This mechanism is central to managing obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), where narrowed airways from smooth-muscle contraction, inflammation, and mucus contribute to breathing difficulty. Beta-2 agonists are frequently combined with inhaled corticosteroids, which address underlying airway inflammation, or with agents that block a different receptor pathway (muscarinic antagonists), reflecting the complementary, multi-pathway nature of airway disease management.

By indication

Related mechanisms

Beta-2 adrenergic receptor drugs compared

17 drugs, stage by indication
17 drugs acting on Beta-2 adrenergic receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Aclidinium bromide/formoterol fumarateDuaklir PressairAlmirall, Azurity Pharmaceuticalssmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
albuterol (Armstrong Albuterol HFA)Amphastar Pharmaceuticals, Inc.small moleculeApprovedApproved in Asthma
albuterol (Ventolin)VentolinGlaxoSmithKlinesmall moleculeApprovedApproved in Asthma
albuterol / budesonideAirsupraAstraZenecacombination (SABA + ICS)ApprovedApproved in Asthma
albuterol sulfate (Amphastar)Amphastar Pharmaceuticals, Inc.small moleculeApprovedApproved in Asthma
Albuterol sulfate (Proventil HFA)Proventil HFAKindeva Drug Delivery, Sandoz Group AGsmall moleculeApprovedApproved in Asthma
fluticasone furoate/umeclidinium/vilanterolTrelegy ElliptaGlaxoSmithKlinesmall molecule combinationApprovedApproved in Asthma; Approved in Chronic Obstructive Pulmonary Disease
fluticasone furoate/vilanterolBreo ElliptaGlaxoSmithKlinesmall molecule combinationApprovedApproved in Asthma; Approved in Chronic Obstructive Pulmonary Disease
Fluticasone propionate/salmeterol (Advair HFA)Advair HFAGlaxoSmithKlinecombination (ICS + LABA)ApprovedApproved in Asthma
Glycopyrrolate/formoterol fumarateBevespi AerosphereAstraZenecasmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
OlodaterolBoehringer Ingelheimsmall moleculeApprovedApproved in Chronic Obstructive Pulmonary Disease
Olodaterol/tiotropium bromideBoehringer Ingelheimsmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
Salmeterol (DISKUS)GlaxoSmithKlinesmall moleculeApprovedApproved in Asthma; Approved in Chronic Obstructive Pulmonary Disease
Umeclidinium/VilanterolGlaxoSmithKline, Innoviva, Sino Biopharmaceuticalsmall molecule combinationApprovedApproved in Chronic Obstructive Pulmonary Disease
fenoterolBoehringer Ingelheimsmall moleculePhase 3Phase 3 in Asthma
Salbutamol HFA-152aGlaxoSmithKlinesmall moleculePhase 3Phase 3 in Asthma
VilanterolGlaxoSmithKlinesmall moleculePhase 3Phase 3 in Asthma

← all mechanisms